Anticipated $-0.14 EPS for OncoSec Medical Incorporated (ONCS) on June, 7

May 17, 2018 - By Mary Gaskins

OncoSec Medical Incorporated (NASDAQ:ONCS) Corporate Logo

OncoSec Medical Incorporated (NASDAQ:ONCS)’s quarterly earnings will be published on June, 7., RTT reports. Analysts expect change of 36.36 % or $0.08 from previous year’s $-0.22 earnings per share compared to current’s $-0.14 earnings per share. After $-0.24 EPS report previous quarter, Wall Street now sees -41.67 % EPS growth of OncoSec Medical Incorporated. ONCS reached $1.78 during the last trading session after $0.07 change.OncoSec Medical Incorporated has 1.54 million shares volume, 30.90% up from normal. ONCS is uptrending and has moved 44.62% since May 17, 2017. ONCS outperformed the S&P500 by 33.07%.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States.The firm is worth $91.64 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer.Currently it has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Another two news for OncoSec Medical Incorporated (NASDAQ:ONCS) were recently announced by: on April 18, 2018 with title “OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner”. The other‘s article was titled “Oncosec Medical (ONCS) Expands Relationship with Merck (MRK); Announces Clinical Collaboration to Evaluate …” and announced on May 08, 2018.

OncoSec Medical Incorporated (NASDAQ:ONCS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.